Gastrointestinal Stent Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Gastrointestinal Stent Market Report is Segmented by Product Type (Biliary Stent, Colonic Stent and More), Material (Self-Expanding Metal Stent, Plastic Stent and More), Application (Biliary Disease, Colorectal Cancer and More), End User (Hospitals, Ambulatory Surgical Centers and More) and Geography (North America, Europe, Asia-Pacific and More). The Market Forecasts are Provided in Terms of Value (USD).

Gastrointestinal Stent Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Gastrointestinal Stent Market with other markets in Healthcare Industry

Gastrointestinal Stent Market Analysis by Mordor Intelligence

The gastrointestinal stent market generated USD 587.80 million in 2025 and is projected to reach USD 763.61 million by 2030, reflecting a CAGR of 5.37% over the forecast window. Rising gastrointestinal (GI) cancer prevalence, a decisive clinical pivot toward minimally invasive endoscopy, and sustained advances in stent design—especially biodegradable and drug-eluting formats—anchor this expansion. Broader use of endoscopic ultrasound (EUS) and artificial-intelligence–guided planning has lowered technical barriers, improved patient-specific customization, and widened procedural suitability, especially for complex pancreaticobiliary disease. North America maintains volume leadership, yet high incidence of colorectal cancer and rapidly modernizing hospital networks position Asia-Pacific as the fastest-advancing region. Robust clinical evidence highlighting cost savings, shorter recovery times, and high patency levels reinforces payer acceptance and accelerates adoption across both malignant and benign indications. 

Key Report Takeaways

  • By product type, biliary stents led with 37.23% revenue share in 2024; colonic stents are forecast to expand at an 8.94% CAGR through 2030.
  • By material, self-expanding metal stents accounted for 61.67% of the gastrointestinal stent market size in 2024, while biodegradable and drug-eluting stents are projected to grow at an 8.79% CAGR to 2030.
  • By application, biliary disease captured 41.46% of the gastrointestinal stent market size in 2024, and colorectal cancer applications are advancing at a 9.23% CAGR through 2030.
  • By end user, hospitals held 64.55% of the gastrointestinal stent market share in 2024; ambulatory surgical centers are set to rise at a 7.89% CAGR over the forecast period.
  • By geography, North America dominated with 35.47% of 2024 revenues, while Asia-Pacific is poised for the fastest 8.23% CAGR through 2030. 

Segment Analysis

By Product Type: Biliary Stents Lead Clinical Applications

Biliary stents held 37.23% share of 2024 revenues in the gastrointestinal stent market, reflecting their entrenched role in malignant and benign biliary obstructions. Laser-cut geometries, hydrophilic coatings, and low-profile delivery catheters foster accurate placement in narrowed ducts and complex hilar lesions. Esophageal and duodenal stents follow in volume, benefitting from improved anti-reflux valves that enhance dysphagia relief. 

Colonic stents supply the fastest 8.94% CAGR through 2030. Comparative studies show self-expandable metal stents deliver survival and quality-of-life outcomes on par with emergent surgery while avoiding colostomy formation. Pancreatic designs without internal flaps record 80.7% spontaneous migration, sparing retrieval procedures and aligning with outpatient protocols. Drug-eluting refinements now target tissue in-growth inhibition, signaling new value propositions across all product classes. 

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Material: Self-Expanding Metal Dominance Challenged by Innovation

Self-expanding metal devices captured 61.67% of 2024 revenue, underlining their balance of radial strength and flexibility. Clinical trials confirm 100% technical success for ileocecal obstruction and 92.3% clinical success, validating adaptability outside the traditional left-sided colon. Advanced nitinol processing, including laser-cut micro-mesh patterns, improves conformability across tortuous anatomy. 

Biodegradable and drug-eluting formats, posting an 8.79% CAGR, answer the call for temporary scaffolding without removal. Iron-based prototypes enhance mechanical reserve while enabling radiopacity tracking. Hybrid constructs bring metallic backbone reliability alongside timed degradation, promising to shift indication boundaries for benign disease management. Plastic remains relevant for short-term drainage when retrieval is planned early, preserving a niche position in the gastrointestinal stent market. 

By Application: Biliary Disease Leadership Amid Colorectal Growth

Biliary disease represented 41.46% of 2024 value, supported by strong guideline endorsement and abundant physician experience. Anti-migration flares, enhanced radiopacity, and fully covered designs reduce tumor in-growth and ease subsequent interventions. Italian consensus recommendations underscore precise sizing and stent selection as outcome determinants. 

Colorectal cancer indications accelerate at a 9.23% CAGR through 2030 as bridge-to-surgery protocols gain oncologic acceptance. Multidisciplinary boards integrate stents with neoadjuvant regimens, improving resection margins and lowering temporary stoma rates. Emerging research into inflammatory bowel disease strictures sparks demand for tailored diameters and softer radial force profiles, hinting at future micro-niche growth. 

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospital Dominance Challenged by Ambulatory Growth

Hospitals controlled 64.55% of 2024 spending, benefiting from anesthesiology, radiology, and critical-care backup fundamental to complex GI interventions. Integrated digital platforms link imaging, AI planning, and post-procedure tracking, reinforcing hospital centrality in high-acuity cases. 

Ambulatory surgical centers advance at 7.89% CAGR, aided by slimline delivery systems and conscious-sedation protocols that shorten stays. Specialty clinics flourish in tertiary hubs, offering pancreaticobiliary expertise and high-throughput scheduling. Portable X-ray and intra-procedure ultrasound options expand point-of-care viability, though stringent patient selection remains essential for safe migration away from inpatient settings. 

Geography Analysis

North America generated 35.47% of 2024 turnover, buoyed by established reimbursement pathways and deep procedural expertise. Medicare’s defined coverage for GI stenting underpins predictable payment cycles, while manufacturer-driven registries furnish real-world evidence that speeds payer updates. United States centers emphasize multidisciplinary tumor boards integrating stenting, chemotherapy, and surgery, sustaining mature demand. Canada’s universal insurance similarly ensures equitable access, fostering stable baseline volumes. 

Asia-Pacific delivers the fastest 8.23% CAGR through 2030, propelled by aging demographics, growing colorectal cancer incidence, and expanded public insurance. China’s hospital upgrade program and regional CRC screening widen procedural addressability. Japan’s super-aged population mandates minimally invasive approaches, while India’s device-marketing code of conduct seeks to balance commercial incentives with ethical outreach. Reimbursement variability and price caps, however, remain decisive adoption throttles, compelling tiered product portfolios targeting affordability. 

Europe displays steady mid-single-digit growth underpinned by harmonized MDR frameworks and robust clinical networks. ESGE-standardized training expands operator proficiency, while cross-border data sharing accelerates technology assessment cycles. Latin America and Middle East & Africa constitute emerging arenas; infrastructure expansion and private-sector hospital investment create runway for advanced endoscopy, yet currency volatility and fragmented insurance dampen immediate penetration. 

Geography growth
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market structure skews toward moderate concentration, with Boston Scientific, Cook Medical, and Olympus leveraging broad GI portfolios, extensive service networks, and acquisition-driven scale. Boston Scientific’s USD 1.26 billion Silk Road Medical deal expands neurovascular crossover know-how into GI delivery-system innovations. Teleflex’s €760 million purchase of Biotronik’s vascular unit signals intent to deepen material science capabilities and adjacent access technology. 

Innovation wars dominate strategic focus. Merit Medical’s WRAPSODY cell-impermeable endoprosthesis achieved 70.1% patency versus 41.6% standard of care, underlining performance-driven product differentiation. Start-ups commercializing 3D-printed personalized stents promise anatomically exact flare diameters and optimized radial force, though scalability and regulatory evidence remain hurdles. 

Supply security and price pressures spur vertical collaboration. OEMs cultivate secondary nitinol sources and adopt laser sintering to internalize component builds, buffering geopolitical supply shocks. Digital service layers—cloud-based planning software, remote proctoring, and AI-driven sizing engines—emerge as stickiness levers, complementing hardware margins and entrenching vendor–provider ecosystems within the gastrointestinal stent industry. 

Gastrointestinal Stent Industry Leaders

  1. Boston Scientific Corporation

  2. Becton Dickinson and Company

  3. Cook Medical

  4. Abbott

  5. Medtronic

  6. *Disclaimer: Major Players sorted in no particular order
Gastrointestinal Stent Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2024: SafeGuard Surgical received FDA breakthrough designation for its LeakGuard biodegradable stent.
  • January 2024: Olympus completed the acquisition of Taewoong Medical, adding metallic GI stents to its EndoTherapy line.

Table of Contents for Gastrointestinal Stent Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence Of Gi Cancers
    • 4.2.2 Ageing Population & Comorbid Gi Disorders
    • 4.2.3 Shift Toward Minimally Invasive Endoscopy
    • 4.2.4 Rapid Adoption Of Eus-Guided Stenting
    • 4.2.5 Ai-Driven Stent Design & Customization
    • 4.2.6 Technological Advancement And Increasing Adoption Of Biodegradable Stents
  • 4.3 Market Restraints
    • 4.3.1 Device-Related Adverse Events & Re-Interventions
    • 4.3.2 Stringent Multi-Region Regulatory Pathways
    • 4.3.3 Reimbursement Gaps In Emerging Markets
    • 4.3.4 Nitinol Supply-Chain Volatility & Price Spikes
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Product Type
    • 5.1.1 Biliary Stent
    • 5.1.2 Esophageal Stent
    • 5.1.3 Duodenal Stent
    • 5.1.4 Colonic Stent
    • 5.1.5 Pancreatic Stent
  • 5.2 By Material
    • 5.2.1 Self-Expanding Metal Stent (SEMS)
    • 5.2.2 Plastic Stent
    • 5.2.3 Biodegradable / Drug-eluting Stent
  • 5.3 By Application
    • 5.3.1 Biliary Disease
    • 5.3.2 Colorectal Cancer
    • 5.3.3 Stomach Cancer
    • 5.3.4 Inflammatory Bowel Disease
    • 5.3.5 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Ambulatory Surgical Centers
    • 5.4.3 Specialty Clinics
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.3.1 Boston Scientific Corp.
    • 6.3.2 Cook Medical
    • 6.3.3 BD
    • 6.3.4 Olympus Corp.
    • 6.3.5 Merit Medical Systems
    • 6.3.6 CONMED Corp.
    • 6.3.7 Micro-Tech (Nanjing)
    • 6.3.8 S&G Biotech
    • 6.3.9 ELLA-CS
    • 6.3.10 Hobbs Medical
    • 6.3.11 M.I. Tech
    • 6.3.12 Endo-Flex GmbH
    • 6.3.13 BVM Medical
    • 6.3.14 AMG International
    • 6.3.15 ENDOBASE (Spiggle & Theis)
    • 6.3.16 Bioring SA
    • 6.3.17 Medtronic plc

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Gastrointestinal Stent Market Report Scope

As per the scope of the report, gastrointestinal stents are used for the management of obstructive symptoms in the GI tract, which can arise due to diseases of the GI tract, such as malignancies of the stomach, esophagus, duodenum, and pancreas. The Gastrointestinal Stent Market is segmented by Product Type (Biliary Stent, Colonic Stent, Duodenal Stent, Esophageal Stent, and Pancreatic Stent), Application (Biliary Disease, Colorectal Cancer, Stomach Cancer, Inflammatory Bowel Disease, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product Type Biliary Stent
Esophageal Stent
Duodenal Stent
Colonic Stent
Pancreatic Stent
By Material Self-Expanding Metal Stent (SEMS)
Plastic Stent
Biodegradable / Drug-eluting Stent
By Application Biliary Disease
Colorectal Cancer
Stomach Cancer
Inflammatory Bowel Disease
Other Applications
By End User Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Biliary Stent
Esophageal Stent
Duodenal Stent
Colonic Stent
Pancreatic Stent
By Material
Self-Expanding Metal Stent (SEMS)
Plastic Stent
Biodegradable / Drug-eluting Stent
By Application
Biliary Disease
Colorectal Cancer
Stomach Cancer
Inflammatory Bowel Disease
Other Applications
By End User
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current size of the gastrointestinal stent market?

The market generated USD 587.80 million in 2025 and is forecast to climb to USD 763.61 million by 2030 at a 5.37% CAGR.

2. Which product category holds the largest share?

Biliary stents lead with 37.23% revenue share due to their central role in managing malignant and benign biliary obstructions.

3. Why are biodegradable stents gaining traction?

Biodegradable designs eliminate retrieval procedures, reduce long-term adverse events, and are projected to grow at an 8.79% CAGR, the fastest among material

4. Which region is expanding the fastest?

Asia-Pacific shows the highest 8.23% CAGR, driven by rising colorectal cancer incidence, healthcare infrastructure upgrades, and broader insurance coverage.

5. What are the main clinical drivers for market growth?

Key growth factors include increasing GI cancer prevalence, ageing populations with comorbidities, rapid uptake of EUS-guided techniques, and ongoing shifts toward minimally invasive endoscopy.

Page last updated on: June 21, 2025

Gastrointestinal Stent Market Report Snapshots